Related by context. All words. (Click for frequent words.) 64 metaanalysis 63 randomized controlled trials RCTs 62 prospective observational studies 62 CARE HF 61 selenium supplementation 61 ECASS 61 Meta analyzes 61 meta regression 61 riociguat 61 preclinical pharmacokinetic 61 Mechanistic studies 60 PROactive study 60 Subgroup analysis 60 retrospective cohort 60 Cochrane reviewers 60 PRIMO CABG 60 BARI 2D 60 CYP#D# inhibitor 60 Carotid Revascularization Endarterectomy vs. 60 number NCT# ClinicalTrials.gov 60 HIV HCV coinfected 60 Clinical Antipsychotic Trials 60 darbepoetin alpha 59 randomized controlled clinical trials 59 breast cancer recurrences 59 VADT 59 Intervention Trial GAIT 59 CAMMS# 59 underwent coronary angiography 59 papillary renal cell carcinoma 59 HYVET 59 STRIDE PD 58 visceral metastases 58 journal Gynecologic Oncology 58 Dr. Pasinetti 58 Shelley Salpeter 58 Xelox 58 ExTRACT TIMI 58 Subgroup analyzes 58 ALLHAT 58 ConclusionThis 58 enteroviral infection 58 INTERHEART study 58 relapsed MM 58 RECORD1 58 CARDIA study 58 placebo controlled studies 58 statins cholesterol lowering 58 Evaluation WISE 58 multicenter trials 58 coinfected patients 58 Val HeFT 57 ACOSOG Z# 57 Intervention Effectiveness CATIE 57 preclinical pharmacology 57 randomized controlled trials 57 Singh Manoux 57 PLCO trial 57 Cochrane Systematic Review 57 prospective observational cohort 57 Observational studies 57 EDEMA3 trial 57 Intervention Effectiveness 57 HBV infections 57 HMG CoA reductase inhibitors 57 antitumor effect 57 Digital Mammographic Imaging 57 Dr. Tashkin 57 #rd Annual CTRC 57 Dr. Roehrborn 57 Enzastaurin 57 Post mortem examination 57 dyslipidaemia 57 HCV RESPOND 2 57 ACCORD Lipid 57 fosbretabulin 57 RE LY trial 57 Edge STudy 57 meta analyzes 57 intravascular hemolysis 57 cancer chemoprevention 57 Lancet Oncology journal 57 BRIM3 57 Schunkert 57 NATRECOR ® 57 plasma pharmacokinetics 57 Glucosamine Chondroitin Arthritis 57 genomewide association study 57 journal Resuscitation 57 dietary questionnaires 57 Rigorous scientific 56 prospective multicentre 56 Histopathological 56 STEP BD 56 CHARISMA trial 56 journal Lancet Neurology 56 Randomized trials 56 immunohistochemical 56 flavopiridol 56 RIO Lipids 56 journal Cephalalgia 56 multicenter Phase II 56 Teriflunomide 56 CALERIE 56 galiximab 56 EOquin TM phase 56 prospective longitudinal 56 teriflunomide 56 squamous cell lung cancer 56 demonstrated antitumor activity 56 homocysteine concentrations 56 landmark ATHENA 56 Women Ischemia Syndrome 56 florbetaben 56 cilostazol 56 ONTARGET 56 CALGB 56 Cardiorespiratory fitness 56 BEZ# 56 phase IIb study 56 clevidipine 56 PRIMO CABG2 56 PERSEUS 56 prospective nonrandomized 56 infantile colic 56 Multicenter AIDS 56 hematopoietic cancers 56 Screening Trial DMIST 56 journal Nucleic Acids 56 reboxetine 56 NMDA receptor antagonists 56 reanalysed 56 aldosterone antagonists 56 preclinical efficacy 56 isoflavone supplement 56 placebo controlled clinical 56 MGd 56 prognostic indicators 56 limiting generalizability 56 CHAMPION PCI 56 CombAT study 56 β blockers 56 SPARCL 56 neratinib 56 AVERROES 56 novel VDA molecule 56 mutated BRAF gene 56 Genitourinary Cancers Symposium 56 HCV SPRINT 56 EEG abnormalities 55 AIR2 Trial 55 Wisconsin Sleep Cohort 55 retrospectively analyzed 55 genotypic resistance 55 BMC Musculoskeletal Disorders 55 ToGA 55 journal Carcinogenesis 55 Raloxifene STAR 55 CTEPH 55 HORIZONS AMI trial 55 synthetic lethality 55 Pharmacokinetic parameters 55 BoNTA 55 journal Urology 55 undergone radical prostatectomy 55 colorectal adenoma 55 AML MDS 55 pharmacologic stress 55 colorectal liver metastases 55 HORIZONS AMI 55 antiangiogenic therapy 55 Phase III AFFIRM 55 IMPROVE HF 55 recurrent malignant glioma 55 NCCTG N# 55 lenalidomide Revlimid R 55 cardioprotective effects 55 urodynamic 55 clinico pathological 55 Prostate Lung Colorectal 55 beta carotene supplementation 55 placebo controlled trials 55 fluvastatin 55 neurologic progression 55 invasive lobular carcinoma 55 journal Molecular Psychiatry 55 toxicologic 55 GSK# [002] 55 oral rivaroxaban 55 Human Reproduction journal 55 genetic polymorphisms 55 Munk Olsen 55 multicenter placebo controlled 55 Monique MB Breteler 55 Akt inhibitor 55 Vlachopoulos 55 paricalcitol 55 prostate carcinogenesis 55 MAGE A3 ASCI 55 antiangiogenic activity 55 Prostate AdenoCarcinoma Treatment 55 GRNCM1 55 renal cell carcinomas 55 multicenter randomized controlled 55 pharmacodynamic parameters 55 pivotal bioequivalence 55 elevated ALT 55 SORT OUT III 55 impaired insulin secretion 55 lymphomas leukemias 55 carotid atherosclerosis 55 nonrandomized studies 55 PLX STROKE targeting 55 obstructive coronary 55 olaparib 55 tolvaptan 55 SABCS 55 perampanel 55 meta analysis 55 BEXXAR Therapeutic Regimen 55 EMPHASIS HF trial 55 pyridostigmine 55 PARTNER Trial 55 Arch Surg 55 NSABP B 55 Proellex TM 55 Randomized clinical trials 55 chromium supplementation 55 Epidemiologic studies 55 angiographically 55 Cholesterol Levels SPARCL 55 Serological 55 Lp PLA 2 55 lipid lowering therapy 54 Abdominal ultrasound 54 BUSM researchers 54 antioxidant supplementation 54 APPRAISE 54 ADVEXIN therapy 54 allogeneic HSCT 54 preclinically 54 postmarketing adverse 54 CRLX# 54 Lancet Neurology journal 54 SAR# [004] 54 motesanib 54 silent ischemia 54 bronchial lavage 54 ACCORD Eye 54 Aggressive Reduction 54 subgroup analyzes 54 sirtuin activators 54 antisense inhibition 54 lipid lowering drugs 54 vitro experiments 54 biochemical abnormalities 54 Avandia Actos 54 Primary endpoints 54 Electrophysiological 54 CYT# potent vascular disrupting 54 perioperatively 54 UKPDS 54 Arterial stiffness 54 genomic biomarker 54 CALGB # [002] 54 pharmacodynamic markers 54 CA9 SCAN 54 ralfinamide 54 trastuzumab DM1 54 metabonomics 54 journal Ophthalmology 54 elevated bilirubin 54 endothelin antagonists 54 LHRH receptor positive 54 antiretroviral naïve 54 oncologic outcomes 54 Multivariate logistic regression 54 AACR San Antonio 54 Acta Scandinavica 54 ICON7 54 telomere lengths 54 Cochrane Database 54 duplex ultrasonography 54 GERD migraine headaches 54 unresectable tumors 54 AVAiL 54 pharmacodynamic effects 54 phase Ib 54 dose statin therapy 54 Prostate Cancer Prevention 54 cardiovascular morbidity 54 Alan Dangour 54 dose proportionality 54 CLARITY TIMI 54 prospective observational 54 torcetrapib atorvastatin 54 fidaxomicin Phase 3 54 intermittent dosing 54 antihypertensive therapy 54 methodological limitations 54 Phase 1a clinical 54 tumor subtype 54 coxib 54 BCIRG 54 Boffetta 54 sorafenib Nexavar 54 stratifying patients 54 abstracts summarizing 54 chemoprevention trials 54 neuroimaging studies 54 Ronald DePinho 54 BACcel ™ system 54 ASTEROID 54 kidney urologic 54 pharmacokinetic PK study 54 phase IIIb 54 PREVENT IV 54 CaPSURE 54 HF ACTION 54 Zemiva imaging 54 thiazide diuretics 54 Gynecologic Oncology Group 54 blinded randomized controlled 54 RE LY ® 54 autopsied brains 54 basal bolus regimen 54 IQWiG 54 intracranial stenosis 54 journal BJU International 54 topical NSAIDs 54 randomized trials 54 subclinical disease 54 prostate cancer CaP 54 nonrandomized 54 endocrinologic 54 Hwang fabricated 54 nonfasting 54 weekly subcutaneous injections 54 RRMS patients 54 atherothrombosis 54 Coronary angiography 54 sex hormones estradiol 54 Nephrology Dialysis Transplantation 54 ARB telmisartan 54 Demark Wahnefried 54 TG MV 54 exploratory endpoints 54 preoperative chemotherapy 54 probiotic supplementation 54 hypermethylated 54 bladder ovarian 54 AIR CF1 54 Lipid Lowering Treatment 54 multicentric 54 ThermoDox ® clinical 54 GPC5 54 Chicago Multidisciplinary Symposium 53 intensive statin therapy 53 placebo controlled clinical trials 53 trial evaluating PRX# 53 prucalopride 53 Ismail Beigi 53 DASISION 53 prognostic markers 53 Skin sterol 53 journal Diabetologia 53 attain statistical significance 53 diagnosing ADHD 53 SIMPADICO 53 scintigraphic 53 canagliflozin 53 nabilone 53 Serum potassium 53 serum estradiol 53 patients undergoing CABG 53 #F FDG PET 53 relapsing remitting MS RRMS 53 Serebruany 53 ATACAND 53 telomerase inhibition 53 Renal Cell Carcinoma RCC 53 journal CHEST 53 TRITON TIMI 53 generalisability 53 biologic plausibility 53 prelicensure 53 Dr. Vitetta 53 Afatinib 53 serum lipid levels 53 & Analgesia retracted 53 NP2 Enkephalin 53 ovarian endometrial 53 serum lipids 53 PROTEGE trial 53 HOPE TOO 53 BETAS 53 ENESTnd 53 follicular adenoma 53 Diabetologia 53 irbesartan 53 randomized clinical trials 53 inflammatory biomarkers 53 TAXUS VI 53 S. maltophilia 53 OBPM 53 extrapulmonary disease 53 Val MARC 53 desvenlafaxine succinate 53 EBUS FNA 53 alvespimycin 53 skin sterol 53 longitudinal observational study 53 paroxetine Seroxat 53 blood clot dissolving 53 platelet activation 53 FDG PET scans 53 corrected QT interval 53 FDG-PET/CT 53 GAMMAGARD 53 trastuzumab Herceptin ® 53 journal Phytotherapy Research 53 EUS FNA 53 hsCRP levels 53 RE LY 53 R rosiglitazone maleate 53 laser Doppler 53 multiple logistic regression 53 carotid plaque 53 inhibit angiogenesis 53 Phase Ib II 53 KRAS variant 53 ASSERT trial 53 XMRV infection 53 thrombophilia 53 coronary calcification 53 rALLy trial 53 CIMZIA TM certolizumab pegol 53 bovine thrombin 53 Cardiotoxicity 53 Rasenick 53 Bengt Winblad 53 HGS# 53 dose escalation Phase 53 KIF6 gene variant 53 Paul Thornalley 53 radiographic findings 53 midstage trials 53 journal Arteriosclerosis Thrombosis 53 neuropsychiatric symptoms 53 HER2 positive cancers 53 preoperative MRI 53 confirmatory clinical 53 APPROVe trial 53 chest radiographs 53 Candesartan 53 Multivariate analyzes 53 AVOREN 53 eculizumab therapy 53 NATRECOR R 53 Vaccine Immunology 53 induced sputum 53 undergoing peritoneal dialysis 53 Renata Pasqualini 53 longitudinal cohort 53 Molecular Cancer 53 Tor Bjerkedal report 53 PSMA ADC 53 immunological responses 53 journal Rheumatology 53 immunohistochemical staining 53 parenteral antibiotics 53 CINQUIL 53 placebo controlled multicenter 53 aspirin clopidogrel 53 Dengue Hemorrhagic Virus 53 relapsed ALL 53 #q# deletion 53 albiglutide 53 Health Initiative Observational 53 symptomatic VTE 53 bazedoxifene conjugated estrogens 53 ABCB1 53 Kenneth Shorrock 53 axitinib 53 ALB # 53 multicentre prospective 53 radiolabeled TM# 53 muraglitazar 53 Phase IIIb study 53 GFT# 53 epoetin alpha 53 deCODE AF TM 53 carotid IMT 53 Hertzel Gerstein 53 Immunohistochemical analysis 53 obstructive coronary artery 53 Simin Nikbin Meydani 53 pharmacokinetic pharmacodynamic 53 maximally tolerated dose 53 ximelagatran 53 Michael F. Leitzmann 53 trastuzumab emtansine T DM1 53 surveys Herbenick 53 enzastaurin 53 TLR antagonists 53 methodologically rigorous 53 randomized multicenter trial 53 chromosome aberrations 53 diabetic kidney 53 abnormal glucose tolerance 53 Glucosamine chondroitin Arthritis 53 XZK 53 HER2 overexpression 53 genetically reprogramming 53 inhibit platelet aggregation 53 Zheng Cui 53 perineural invasion 53 Helicobacter infection 53 HIV coinfected 53 intracranial atherosclerosis 53 BMC Biology 53 Multiple logistic regression 53 sonographic diagnosis 53 DHEA supplementation 53 invasive lobular 53 RTOG 53 Eric Kossoff 53 coinvestigators 53 Multivariate analysis 53 Howard Sesso 53 multicenter phase 53 colorectal neoplasia 53 untreated metastatic melanoma 53 Swedish Mammography Cohort 53 allergic airway inflammation 53 HAART regimens 53 AVADO 53 refractory CLL 53 colorectal adenocarcinoma 53 Shlipak 53 Redei 53 evaluating mipomersen 53 microdialysis 53 LRP5 53 Dr. Gabriel Lasala 53 Sibutramine Cardiovascular Outcomes 53 NPM1 mutations 53 Karolinska Institute Stockholm 53 gallium nitrate 53 candesartan cilexetil 53 ragweed allergic 53 elevated CRP 53 hepatic fat 53 ARCOXIA 53 Pharmacodynamic 53 F FDG PET 53 embryo biopsy 53 testosterone supplementation 53 neuropathologic 53 tibolone 53 detect XMRV 53 phase IIa clinical 53 hypersensitivity allergic reactions 53 Zevalin consolidation 52 Phase Ib clinical 52 thorough QT 52 atherothrombotic disease 52 Bresalier 52 viral kinetic 52 retrospective cohort study 52 vivo experiments 52 PCNSL 52 poststroke depression 52 tipranavir ritonavir 52 generalisable 52 journal PNAS Proceedings 52 clinicopathological 52 nonpharmacologic 52 prenatal exposures 52 gadobutrol 52 trials RCTs 52 Phase III ADT 52 untreated metastatic colorectal 52 MERLIN TIMI 52 AIR CF2 52 barbiturates benzodiazepines 52 hypercholesterolemic patients 52 journal Nature Immunology 52 spontaneous regression 52 biostatistical analysis 52 impair fertility 52 PLCO 52 Shamay Tsoory 52 etiologic 52 liver transplant recipients 52 PCI ExTRACT TIMI 52 myocardial infarctions MIs 52 lowering homocysteine levels 52 perfusion CT 52 REACH Registry 52 LC#m# vaccine 52 serum vitamin D 52 immunohistochemical analysis 52 serologic 52 CoQ# supplementation 52 ischemic cardiovascular 52 induced tumor regression 52 maternal serum 52 Atkins dieters cardiovascular 52 EXPLORE Xa 52 MADIT II 52 morphometric vertebral fractures 52 journal Circulation Cardiovascular 52 Marc Sabatine 52 Arteriosclerosis Thrombosis 52 journal Transfusion 52 journal Chemosphere 52 Clinicaltrials.gov 52 pharmacokinetic parameters 52 thyroid carcinoma 52 microarray experiments 52 Montalescot 52 postmenopausal hormones 52 Randomized controlled 52 lomitapide 52 Cohort Study MACS 52 Phase 1b clinical trials 52 pathologic examination 52 Ulleval University 52 journal Psychological Bulletin 52 artery calcification 52 predictive validity 52 paroxetine Paxil 52 carotid artery blockage 52 developmental neurotoxicity 52 Towering scholar 52 pathogenetic mechanisms 52 human IgG1 monoclonal 52 methacholine challenge 52 Schaffir 52 TCF#L# gene 52 Institute DCRI 52 susceptibility loci 52 dietary modification 52 nonclinical studies 52 bronchopulmonary dysplasia BPD 52 Okunieff 52 Cloretazine R 52 J Clin Oncol 52 transcranial Doppler ultrasound 52 atherogenic dyslipidemia 52 fasting glucose levels 52 subanalysis 52 methotrexate therapy 52 Stephanie Belloc 52 OncoVex 52 Saliva samples 52 Phase IIA 52 HIV seroconversion 52 pretreatment serum 52 GBA mutations 52 myocardial ischemia 52 mTOR inhibition 52 CTRC AACR San Antonio 52 Phase 1b trial 52 Alpha Tocopherol Beta Carotene 52 Epidemiological studies 52 cannabinor 52 HIV tropism 52 serum GGT 52 metabolite concentrations 52 adenoma recurrence 52 estrogen progestin therapy 52 journal Menopause 52 untreated CLL 52 prospective multicenter study 52 journal Neuropsychopharmacology 52 eprotirome 52 urocortin 2 52 Post hoc 52 NHANES III 52 recurrent venous thromboembolism 52 serum cholesterol 52 elevated triglycerides 52 intravenous CK # 52 Hypertensive adverse reactions 52 persistent pulmonary hypertension 52 chlamydial infection 52 gallstone disease 52 bronchoalveolar 52 cerebral microbleeds 52 Laheru 52 genomewide 52 C. pneumoniae 52 immunopathology 52 circulating endothelial cells 52 Human Mutation 52 antibiotic regimens 52 perimenopausal women 52 viral kinetics 52 CHAMPION PLATFORM 52 hepatic arterial 52 antiplatelet medications 52 thetreatment 52 ORAL Sync 52 NSABP C 52 Lymph node 52 APPROVe 52 Phytotherapy Research 52 gene expression datasets 52 Doxil ® 52 haematological 52 neutrophil gelatinase associated lipocalin 52 engineered urethras 52 multicenter prospective 52 iPrEx 52 ABSORB trial 52 Tsimikas 52 neuritic 52 rimonabant Acomplia 52 RCTs 52 carotid stenosis 52 Michael Leitzmann 52 prospectively defined 52 REMINYL ® 52 chlorthalidone 52 colleague Sana Inoue 52 pharmacologically relevant 52 nonvertebral fractures 52 resected pancreatic cancer 52 ACRIN 52 Anders Hviid 52 Proteome Research 52 NICE SUGAR 52 glomerular filtration 52 journal Hepatology 52 EC Cysteamine 52 Neugut 52 PSN# [002] 52 ginkgo extract 52 Multiethnic Study 52 James Cerhan MD 52 IMPACT DCM 52 tumor histology 52 ALK inhibitors 52 Elocalcitol 52 anti arrhythmic drug 52 strontium ranelate 52 perfusion defects 52 Aspergillus nidulans 52 CMV infections 52 Mayo Clinic oncologist 52 Deutsches Arzteblatt International 52 Dr. Fehlings 52 SE5 OH containing 52 Lp PLA2 52 CYP#D# genotype 52 recurrent metastatic 52 randomized controlled multicenter 52 GISSI HF 52 underwent angiography 52 Dietary Modification Trial 52 B vitamin supplementation 52 gastric adenocarcinoma 52 Colon polyps 52 Sackner Bernstein 52 Natural S equol 52 undergoing coronary angiography 52 Telintra 52 gadolinium enhanced 52 Phase IIIB IV 52 pharmacokinetic characteristics 52 localized renal 52 abnormal cytology 52 Screening Trial 52 pertuzumab 52 Piccart 52 prognostic variables 51 ENHANCE study 51 Ascherio 51 BRAF gene mutations 51 Ribavirin causes 51 Longitudinal studies 51 placebo controlled randomized 51 acute toxicity 51 davunetide intranasal AL 51 chemopreventive agents 51 spirometric 51 Antihypertensive 51 NHAMCS 51 CLL8 51 postmenopausal hormone therapy 51 STK# gene 51 familial aggregation 51 ARBITER 6 51 obese postmenopausal 51 CARDIA 51 hematological parameters 51 Psychoneuroendocrinology 51 venlafaxine XR 51 genomewide association studies 51 G. biloba 51 pharmacokinetics PK 51 Intervention Trial 51 antithrombotic therapy 51 stone formers 51 herb black cohosh 51 atorvastatin Lipitor 51 Zemplar Capsules 51 pancreatic prostate 51 Alzheimer Disease Cooperative 51 BMC Psychiatry 51 bladder tumors 51 CVD mortality 51 Hilakivi Clarke 51 experimentally validated 51 ASCO Breast Cancer 51 intestinal biopsy 51 FFR measurements 51 Clinical Infectious Disease 51 Tasigna prolongs 51 Circulation Heart Failure 51 Dickersin 51 substudy 51 ELISpot 51 LUMINATE 51 haematologic 51 ORMD 51 VentureOne proprietary 51 #:#-# [029] 51 Weese Mayer 51 adjuvant colon cancer 51 hemodynamically stable 51 neurodevelopmental outcome 51 TASKi3 51 S#A# [002] 51 Lancet journal 51 REVIVE Diabetes 51 fibrate drugs 51 cyclophilin inhibitors 51 Dr. Gianni Belcaro 51 TAXUS ARRIVE 51 vivo coagulation 51 ductal adenocarcinoma 51 Sudbo 51 anastrazole 51 prospectively enrolled 51 KIF6 carriers 51 journal Palaios 51 subthreshold depression 51 Arch Intern Med 51 Pharmacokinetic studies 51 REALITY Trial 51 underlying molecular mechanisms 51 Vertos II 51 journal Langmuir 51 Phase III multicenter 51 ancrod 51 randomized blinded 51 APEX AMI 51 redox active 51 spontaneous preterm delivery 51 randomized Phase IIb 51 ADVANCE PD 51 Circulatory Physiology 51 histopathological 51 Pharmacologic 51 PORxin TM platforms 51 elevated LDL cholesterol 51 ongoing Phase IIIb 51 Oral NKTR 51 double blinded randomized 51 QTinno 51 cerebrospinal fluid biomarkers 51 treatment naive genotype 51 journal Epilepsia 51 Nikolaos Scarmeas MD 51 phytoestrogen intake 51 atherosclerotic renal artery stenosis 51 Arch Neurol 51 molecular biomarker 51 bepotastine besilate nasal spray 51 Neuropsychologia 51 RECIST Response Evaluation Criteria 51 Soffritti 51 p# biomarker 51 AIM HIGH 51 DMIST 51 intravenous bisphosphonates 51 transient elastography 51 CLA supplementation 51 Multivariable logistic regression 51 Sociodemographic 51 microarray datasets 51 bone density measurements 51 INTERMAP 51 facial clefts 51 enzyme inhibition 51 severe gastroparesis 51 gene expression microarrays 51 #th Annual Interscience 51 phylogenetic analyzes 51 comorbid ADHD 51 tesofensine 51 Hurthle cell 51 longitudinal cohort study 51 modulate ion channels 51 YONDELIS 51 Berislav Zlokovic MD Ph.D. 51 MMP inhibitors 51 adiponectin levels 51 journal Pharmacotherapy 51 SIRT1 activation 51 plasma adiponectin 51 Dr. Montori 51 journal Liver Transplantation 51 nondiabetics 51 elective percutaneous coronary 51 Fulvestrant 51 schizophreniform disorder 51 micrometastasis 51 journal Anaesthesia 51 journal Lancet Oncology 51 bacterial isolates 51 colorectal neoplasms 51 celecoxib 51 tumor subtypes 51 hepatic lesions 51 modified REGENESIS Phase IIb 51 Diabetes ACCORD 51 Breteler 51 noscapine 51 preterm newborns 51 folate vitamin B 51 Hashibe 51 silymarin 51 pain palliation 51 ORMDL3 51 biochemical assays 51 Wactawski Wende 51 symptomatic pulmonary embolism 51 novel oral anticoagulant 51 urine cytology 51 borderline statistical significance 51 EMPOWER ™ 51 phase Ib clinical 51 nodal metastasis 51 CMV antibodies 51 cystoscopic 51 familial clustering 51 oral deforolimus 51 deforolimus 51 ACNP 51 subclinical atherosclerosis 51 Limperopoulos 51 Clinical Gastroenterology 51 pelvic malignancies 51 liver biopsies 51 Therapeutic Advances 51 Phase IIb III 51 Ocular Hypertension Treatment 51 Late Breaker 51 Onconase 51 biologic pathways 51 Oreopoulos 51 EDEMA3 51 extracolonic findings 51 PFO migraine 51 Chodick 51 sputum specimens 51 SYMMETRY trial 51 gene predisposing 51 bowel polyps 51 microbiologically evaluable 51 carotid bruit 51 journal Contraception 51 dietary nitrite 51 metabolic parameters 51 Hotamisligil 51 BOLDER II 51 vitro studies 51 ginkgo biloba extract 51 Netherlands Cohort Study 51 retrovirus XMRV 51 ASCEND HF 51 hydroxychloroquine 51 antiplatelet drugs 51 journal Animal Behaviour 51 pulmonary toxicity 51 Psycho Oncology 51 Frobell 51 PreCISe 51 MADIT CRT trial 51 contralateral breast cancer 51 ptau 51 electroencephalographic 51 ADAS Cog 51 phase IIa 51 tamoxifen therapy